46 results about "Immune serums" patented technology

The invention discloses a purification method for removing endotoxin in prokaryotic expression recombinant protein, which belongs to the technical field of bioengineering, and comprises the following steps: adding 0.1% Triton X-114 in an ultrasonication stage, carrying out ice-bath ultrasonication, after the recombinant protein is combined with a Ni-NTA affinity column, washing with 50 column volumes of a combination buffer solution containing 0.1% Triton X-114, and carrying out elution by using an elution buffer solution containing 0.1% Triton X-114 in the presence of an elution buffer solution containing 0.1% Triton X-114 in the presence of an elution buffer solution containing 0.1% Triton X-114 in the presence of an elution buffer solution containing 0.1% Triton X-114; and washing with a 4-DEG C binding buffer solution with 20 column volumes, and subsequently eluting the target protein with imidazole with different gradients. Then, regulating the pH value of the purified recombinant protein solution to 2-4 or more than 10 through 100mM hydrochloric acid or sodium hydroxide, dissociating and decomposing endotoxin, carrying out oscillation treatment at room temperature for 2-4 hours, then removing the endotoxin in the recombinant protein through ultrafiltration, retaining an endotube protein solution, and detecting the content of protein and the endotoxin in the recombinant protein; the method is easy and convenient to operate and low in cost, the endotoxin content in the recombinant protein prepared through prokaryotic expression can be reduced by 400 times on the premise that immune recognition of the recombinant protein and serum is not affected, and the phenomenon that strong cross reaction occurs between immune serum and escherichia coli due to high endotoxin residues in the recombinant protein is reduced.

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The invention belongs to the technical field of molecular biology, and discloses a truncated outer membrane protein of klebsiella pneumoniae and application thereof. The invention provides an outer membrane protein Lol B of klebsiella pneumoniae, which can be used for immunizing to induce a protective antibody aiming at various serotypes of klebsiella pneumoniae and killing the klebsiella pneumoniae. Specifically, the outer membrane protein Lol B immune serum can efficiently kill Klebsiella pneumoniae, and when a mouse immunized by the outer membrane protein Lol B immune serum is attacked by K1, K2 and K6 serotype Klebsiella pneumoniae, the mouse can be completely protected to survive, and the trend of weight loss of the mouse is remarkably reduced. Therefore, the outer membrane protein Lol B provided by the invention has a clinical application value for preventing and treating klebsiella pneumoniae infection.

A general formula for lysins based on which the activity and functionality are further screened and 24 lysins are identified and further investigated, nine of which are characterized. These lysins exhibit potent bactericidal activity, capable of lysing multiple species of Staphylococcus, Streptococcus, and / or Enterococcus; demonstrate robust environmental resistance and stability, retaining activity under varying temperatures, NaCl concentrations, pH levels, and in immune serum; and effectively treat localized and systemic infections. These lysins and their variants are promising as antimicrobial agents for eradicating bacteria, preventing bacterial infections, or treating bacterial infections (caused by genera Staphylococcus, Streptococcus, and / or Enterococcus).

The application discloses a kind of areca alkaloid artificial hapten, artificial antigen and its preparation method and application, with norarecoline hydrochloride as the starting material for synthesizing artificial hapten.This areca alkaloid artificial hapten retains the characteristic structure of areca alkaloid to the greatest extent, and has active groups that can couple with carrier proteins, which can be used as antigenic determinants;Further, the areca alkaloid artificial antigen obtained can be used to immunize to obtain an anti-areca alkaloid artificial antibody with high affinity, high sensitivity and strong specificity.The titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:70000, and can be used for rapid and accurate immunodetection and immunoassay of areca alkaloid.

The invention discloses a polyclonal antibody of panda Rbp7 protein as well as a preparation method and application thereof, and belongs to the technical field of antibodies. The first to nineteenth amino acid sequences of the panda Rbp7 protein are used as antigen polypeptides, and are specifically shown as SEQ ID No.1. After chemical synthesis or exogenous expression purification, a Balb / C mouse is immunized, and the polyclonal antibody is obtained through repeated immunization, serum titer detection and affinity chromatography purification. The titer of the antibody is not lower than 1 / 128000, the panda Rbp7 recombinant protein can be efficiently and specifically detected through WB and ELISA, the blank of a protein detection tool is filled, and reliable technical support is provided for research on the functional mechanism of the panda Rbp7 protein.

The application discloses a method for improving the sensitivity of a porcine circovirus type 2 Cap protein antigen agar diffusion detection, and belongs to the technical field of veterinary products. The method is as follows: (1) inoculating piglets with a porcine circovirus 2a, 2b and 2d trivalent virus-like particle vaccine, and then separating serum to obtain a porcine circovirus 2a, 2b and 2d trivalent high-immune serum; (2) preparing a high-salt agar plate; (3) diluting the trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen with a high-salt diluent, respectively, and then adding the diluted trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen into holes of the agar plate, and incubating at 35-37 DEG C for 20-24 h to complete the detection. The application uses high-immune serum and an improved agar diffusion method to quantitatively detect the content of PCV2 Cap protein, and avoids the defects of low tolerance to buffer reagents and poor detection specificity of the commonly used BCA or Bradford protein content detection method.

The application discloses a colloidal gold test strip for distinguishing between wild toxin infection and vaccine immunization of porcine pleuropneumonia actinobacillus and application. The test strip of the application takes ApxIVA truncated protein with an amino acid sequence shown as SEQ ID NO. 3 as an antigen, the truncated protein can be soluble expressed in E. coli, and the structure and function of the truncated protein are close to those of natural apxIVA. The test strip of the application comprises a sample pad, a colloidal gold pad, an NC membrane, a water absorption filter paper and a bottom plate, the colloidal gold pad is coated with gold-labeled apxIVA truncated protein and gold-labeled chicken IgY antibody, and the C line and the T line of the NC membrane are fixed with goat anti-chicken IgY antibody and apxIVA truncated protein. The test strip only needs 25 muL of pig serum to make detection within 5-10 min, and can distinguish between APP wild strain infection and gene deletion vaccine APP-HB-04M immunized serum samples.

The present invention belongs to the field of biochemical technology, and specifically relates to an artificial hapten and an artificial antigen for benzhexyphenidyl, as well as a preparation method and application thereof. The molecular structural formula of the artificial hapten for benzhexyphenidyl is shown in Formula (I), and the molecular structural formula of the artificial antigen for benzhexyphenidyl is shown in Formula (II). The artificial hapten for benzhexyphenidyl can be used in the field of preparing anti-benzhexyphenidyl antibodies. The artificial hapten for benzhexyphenidyl of the present invention retains the characteristic structure of benzhexyphenidyl to the greatest extent, and has an active group that can be coupled with a carrier protein, and can serve as an antigenic determinant. The artificial hapten for benzhexyphenidyl obtained by further preparation can be used to immunize and obtain anti-benzhexyphenidyl antibodies with high affinity, high sensitivity, and strong specificity. The titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:256,000, and can be used for rapid and accurate immunodetection and immunoanalysis of benzhexyphenidyl.

Provided are a Dabie bandavirus mRNA vaccine and a preparation method therefor. Specifically an optimized mRNA molecule is provided, and is cloned into a pGEM-3Zf(+)mRNA vaccine vector; the plasmid is linearized by means of enzyme digestion, and subjected to capping and poly(A) tail addition by means of an in-vitro transcriptase method to prepare an mRNA; the obtained mRNA is transfected into eukaryotic cells, and it is verified by means of an immunoblotting experiment that the mRNA can be expressed in vitro; and the mRNA is encapsulated by a lipid nanoparticle delivery system to obtain the mRNA vaccine, which, after immunizing mice, can induce the generation of a relatively high antibody level in serum. A viral neutralization test further proves that the immune serum can bind to viruses to prevent the viruses from infecting cells.

The present application belongs to the technical field of bio-chemical industry, and particularly relates to a lorcaserin artificial hapten, a lorcaserin artificial antigen, and a preparation method and application thereof. The lorcaserin hydrochloride is used as a starting material for synthesizing the artificial hapten, the lorcaserin artificial hapten of the present application retains the characteristic structure of lorcaserin to the greatest extent, and has an active group which can be coupled with a carrier protein, and can be used as an antigenic determinant; the lorcaserin artificial antigen prepared further can be used for immunization to obtain an anti-lorcaserin artificial antibody with high affinity, high sensitivity and high specificity, the titer of the immune serum obtained by immunizing a New Zealand white rabbit is as high as 1:256000, and the immune serum can be used for rapid and accurate immunodetection and immunological analysis of lorcaserin.

The invention discloses a diagnostic method based on mouse lyme disease serology indirect ELISA laboratory, and relates to the technical field of immunoserology detection.The diagnostic method comprises the steps that experimental conditions are optimized through a system, and the optimal reaction system is determined as follows: the antigen coating concentration is 0.2 microgram / microliter, the serum dilution ratio is 1: 200, and the enzyme-labeled secondary antibody concentration is 1: 2000. 0.8), and meanwhile, the antigen dosage is obviously reduced. Dynamic analysis of the antibody shows that the level of the antibody infecting mouse serum reaches a peak 12-25 days after inoculation, and the threshold value of the specific antibody ratio (ArB%) is 71.43%. Researches prove that the method has the characteristics of simplicity and convenience in operation, economy and high efficiency, and is suitable for primary laboratories and large-scale screening. The method provides reliable standardized technical support for lyme disease laboratory diagnosis and epidemiological monitoring.

The utility model discloses a polyclonal antibody immune serum vacuum blood sampling device, and relates to the technical field of blood sampling instruments, the polyclonal antibody immune serum vacuum blood sampling device comprises a blood sampling tube, the upper end and the lower end of the blood sampling tube are not sealed, the upper end opening of the blood sampling tube is connected with an end cover in a clamping mode, the end cover comprises a cover shell, and the cover shell is provided with a sealing cover. A cover shell is arranged in the blood collection tube, a leather plug is embedded in the cover shell, the leather plug is made of an antibacterial elastic material, an airtight self-inspection piece is clamped to a lower end opening of the blood collection tube, the airtight self-inspection piece comprises a transparent sealing shell, and a transparent sealing plug is embedded in the transparent sealing shell. The vacuum degree in the blood collection tube is visually reflected through the elastic membrane cloth, when the elastic membrane cloth deforms, the guide rod and the indicator at the bottom of the guide rod are driven to move together, and the color indication mark is arranged on the indication strip, so that the blood collection tube is convenient to use. And the vacuum degree in the blood sampling tube can be checked by observing the color interval of the indicator on the indication strip.

The present invention discloses a B cell epitope on the surface of a glyceraldehyde-3-phosphate dehydrogenase protein, its nucleic acid molecule, and its application in detecting Mycoplasma hyopneumoniae infection. The B cell epitope of the present invention can be functionally expressed on the surface of an inert carrier S9 bacterium. Based on the LN7-antibody direct-mediated agglutination test detection method established by LN7 functionally expressed on the surface of the S9 bacterium, LN7 specifically recognizes only Mycoplasma hyopneumoniae infection serum antibodies and vaccine immune serum antibodies containing the GAPDH antigen, generating a specific binding reaction, while having no cross-reaction or non-specific binding reaction with other mycoplasma pathogens, porcine respiratory disease pathogen infection serum, and vaccine immune serum. This diagnostic method is expected to become an important technical means for the accurate diagnosis of Mycoplasma hyopneumoniae infection and the monitoring and evaluation of the immune effect of Mycoplasma hyopneumoniae vaccine.

The application belongs to the technical field of antibodies, and particularly relates to an antibody for specifically treating orf of milk goat kids and application thereof. Virus liquid of a diseased goat is collected from a lesion site, and ORFV virus strains are obtained through subculture and amplification of goat skin fibroblasts; milk goats are immunized with a weak vaccine to prepare high-titer immune serum; flow sorting technology is used to separate ORFV-specific B cells from PBMC (peripheral blood mononuclear cells); antibody genes are amplified through nested PCR, expression vectors are constructed, and 293T cells are transfected to express monoclonal antibodies. The monoclonal antibody No. 2 obtained in the application has high affinity and specificity, the heavy chain CDR1-3 region sequence is SEQ ID NO: 1-3, and the light chain CDR1-3 region sequence is SEQ ID NO: 4-6. The antibody can be used for diagnosis, treatment and prevention of orf of goats, and has the characteristics of high efficiency, specificity and stability, and provides a new biological preparation for prevention and control of orf of goats.

The invention discloses a trans-complementary system for producing South African foot-and-mouth disease virus-like particles with transcription and replication capabilities and application of the trans-complementary system. The trans-complementary system comprises a cell line stably transfected with an SAT2FMDV P1 gene and an FMDV-mCherry replicon plasmid, and can be used for producing South African type 2 foot and mouth disease virus-like particles (SAT2FMDV trVLPs) with transcription and replication capabilities. Due to the defect of internal nucleic acid of SAT2FMDV trVLPs, only single-round infectivity exists, safety is high, and biosafety degradation can be achieved. Therefore, the invention also utilizes SAT2FMDV trVLPs to simulate natural virus to establish a serum trace neutralization test system, and replaces the traditional evaluation test of the neutralizing antibody of foot-and-mouth disease positive serum or vaccine immune serum in clinic, so that the SAT2FMDV serum neutralization test can be safely and efficiently completed under the condition of a biosafety secondary laboratory. The invention provides an efficient and safe virology tool, and has huge potential and practical value in the aspects of reducing biological safety risks and simulating SAT2FMDV live virus research.

The invention discloses a monospecific monoclonal antibody for resisting zearalenone-14 glucoside and application of the monospecific monoclonal antibody. An immunogen and a coating antigen are used; the monoclonal antibody capable of monospecifically recognizing the zearalenone-14 glucoside and the rapid detection kit for detecting the zearalenone-14 glucoside are obtained through the technologies of mouse immunization, serum detection, cell fusion, monoclonal screening, ascites induced antibody and the like. The method is suitable for single-specificity trace residue detection of the zearalenone-14 glucoside in samples such as corn, rice, millet, wheat and oat, has very high recognition sensitivity to the zearalenone-14 glucoside, and realizes rapid, large-batch and low-cost detection of the zearalenone-14 glucoside.

The application discloses a monoclonal antibody of immune serum antibody for O-type foot-and-mouth disease virus and application thereof, and relates to the technical field of animal virology and animal infectious disease detection. The application uses vp1 protein as an immunogen, uses polypeptides containing B cell antigen epitopes and inactivated antigens as screening origins respectively, screens out monoclonal antibodies capable of competing with O-type foot-and-mouth disease virus inactivated vaccine and synthetic peptide vaccine immune background serum, and establishes an O-type foot-and-mouth disease virus solid-phase competitive ELISA kit, which greatly shortens the detection time and improves the sensitivity, specificity and stability of the kit.

Disclosed are a pregabalin artificial hapten, artificial antigen and preparation method therefor and application thereof. The structure of the pregabalin artificial hapten is shown as formula (I) and structure of the pregabalin artificial antigen is shown as formula (II). The application is in the preparation for anti-pregabalin antibodies with the pregabalin artificial antigen. The pregabalin artificial hapten retains the characteristic structure of pregabalin to the greatest extent, and has an active group that can be coupled with a carrier protein, and can be used as an antigenic determinant; the pregabalin artificial antigen obtained by further preparation can immune to obtain anti-pregabalin antibodies with high affinity, high sensitivity and strong specificity. The titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:90000, which can be used for rapid and accurate immunoassay of pregabalin.

The invention discloses a B cell epitope peptide based on human papilloma virus E6 protein and application of the B cell epitope peptide in cancer diagnosis. According to the invention, the epitope peptide is displayed and expressed on the surface of an inert carrier bacterium S9H, so that an RI5 epitope peptide-antibody direct mediated agglutination test detection system based on thallus surface epitope display is successfully constructed. Compared with an immunoserological detection technology based on a complete protein antigen, the kit provided by the invention can be used for more specifically, sensitively, conveniently and quickly detecting the virus oncoprotein specific antibody in the body of an HPV persistent infection patient, and can be used for qualitatively and quantitatively determining the content of the antibody. The epitope peptide-antibody direct mediation agglutination test detection technology provides an efficient and reliable new method for accurate diagnosis of dynamic changes of virus oncoprotein antibodies in persistent infection and cancer stages of HPV patients, and has potential important clinical application value.

The application discloses a blocking agent for milk allergen component-specific IgE antibody test strips and application, and belongs to the technical field of immune detection and analysis. The blocking agent uses soybean protein isolate and fish gelatin as the blocking agent in antigen-antibody reaction of immunoserological technology, so as to reduce false negative results caused by using conventional blocking agents, casein and bovine serum albumin, and thus makes the detection result more accurate.

The invention provides a rabbit polyclonal antibody aiming at primary cilia and a preparation method thereof, and belongs to the technical field of biology, and the preparation method comprises the following steps: taking a 200-428 amino acid sequence of human ARL13B protein as a target fragment, synthesizing a gene after codon optimization, cloning the gene to a pet-32a expression vector, and carrying out induced expression in escherichia coli to obtain the rabbit polyclonal antibody aiming at primary cilia. Purifying to obtain high-purity immunogen protein; the nucleotide sequence of the synthetic gene is as shown in SEQ ID NO.1, and the amino acid sequence of the high-purity immunogen protein is as shown in SEQ ID NO.2. Immunizing a New Zealand white rabbit with the high-purity immunogen protein to obtain immune serum; and purifying the immune serum to obtain the rabbit polyclonal antibody. The prepared rabbit polyclonal antibody has higher specificity and signal strength, the titer can reach 1: 64000 or above through ELISA detection, primary cilia can be marked more clearly in a paraffin section immunofluorescence experiment, background noise is remarkably reduced, and the reliability of an experiment result is improved.

The invention discloses a diagnostic antigen of a goat pox virus (GTPV), and belongs to the field of molecular biology. The diagnostic antigen of the goat pox virus (GTPV) belongs to the field of molecular biology. A nucleotide sequence of a coding gene of the antigen is shown as SEQ ID NO.1. The antigen protein has immunogenicity, can be used for immunizing animals to generate a monoclonal antibody with good activity, and can react with GTPV immune serum, so that the antigen protein can be used for serological detection and vaccine immune evaluation of GTPV. The invention also discloses a monoclonal antibody for resisting the antigen, and an application of the antigen and / or the monoclonal antibody in preparation of a GTPV diagnostic kit. According to the invention, GTPV detection of goatpox virus is realized, and the kit has the advantages of high sensitivity and specificity, rapid and convenient detection and the like.

The present application belongs to the technical field of bio-chemical industry, and particularly relates to a nafurexone artificial hapten, an artificial antigen, and a preparation method and application thereof. The nafurexone artificial hapten of the present application retains the characteristic structure of nafurexone to the greatest extent, and has an active group that can be coupled with a carrier protein, and can be used as an antigenic determinant. The nafurexone artificial antigen prepared further can be used to immunize to obtain an anti-nafurexone polyclonal antibody with high affinity, high sensitivity and high specificity. The titer of the immune serum obtained by immunizing a New Zealand white rabbit is as high as 1:128000, and can be used for rapid and accurate immunodetection and immunological analysis of nafurexone.

The invention provides an African swine fever virus antigen fragment and application of the African swine fever virus antigen fragment as a target in subunit vaccines and diagnostic antigens, and the antigen-antibody reaction of clinical ASFV positive pig serum and P30 protein immune mouse serum and monoclonal antibody is compared by performing immunogenicity system identification truncation expression on P30 protein. The humoral immune response potency of each peptide fragment is comprehensively analyzed, and a truncated peptide fragment with remarkable immunological advantages is screened out. The fifth peptide fragment shows strong immunoreactivity in clinical ASFV positive pig serum, and also shows excellent antigen binding characteristic in mouse immune serum and monoclonal antibody. The invention not only provides a new experimental basis for analyzing the action mechanism of the P30 protein in ASFV immunization, but also lays an important foundation for developing a new generation of ASFV subunit vaccines. The research results of the invention deepen the understanding of ASFV P30 protein immune biological functions, and provide important theoretical basis and practical guidance for developing safe and effective African swine fever prevention and control strategies.

The invention provides a nano antigen particle containing an influenza virus NA antigen, an influenza virus vaccine based on the nano antigen particle and application of the influenza virus vaccine. The nano antigen particle can induce an organism to generate a high-level NA specific antibody, and immune serum of the organism can effectively inhibit enzyme activity reaction of homotype NA protein, so that the nano antigen particle has the potential of being developed into influenza virus vaccines.

The present invention discloses a dimethyltryptamine artificial hapten, an artificial antigen, and a preparation method and application thereof. The molecular structural formula of the dimethyltryptamine artificial hapten is shown in Formula I, and the molecular structural formula of the dimethyltryptamine artificial antigen is shown in Formula II. The present invention also discloses the application of the dimethyltryptamine artificial antigen in the preparation of anti-dimethyltryptamine antibodies. The dimethyltryptamine artificial hapten of the present invention retains the characteristic structure of dimethyltryptamine to the greatest extent, and has an active group that can be coupled with a carrier protein, and can serve as an antigenic determinant. The dimethyltryptamine artificial antigen obtained by further preparation can be immunized to obtain anti-dimethyltryptamine antibodies with high affinity, high sensitivity, and strong specificity. The titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:85,000, and can be used for rapid and accurate immunodetection and immunoanalysis of dimethyltryptamine.

The invention provides a lyase general formula, and aiming at the general formula, the activity and the function of the lyase can be further screened. 24 lyases are preliminarily screened out, more specifically, the characteristics of 9 lyases are explored, and the 9 lyases have efficient bactericidal activity and can split various staphylococcus, streptococcus and / or enterococcus; the compound has good environmental resistance and stability, is stable in activity in solutions with different temperatures, different NaCl and different pH values, and is not easy to inactivate in immune serum; and local infection and systemic infection can be effectively treated. The lyase and variants thereof are expected to become antibacterial agents for removing bacteria, preventing bacterial infection or treating bacterial infection (staphylococcus, streptococcus and / or enterococcus bacteria).

The application provides a SARS-related coronavirus universal antigen and a preparation method and application thereof, and belongs to the technical field of immunity. The candidate antigen prepared by the application has higher S309 antibody and detection serum binding activity, the titer of serum obtained by immunizing mice with the candidate antigen has higher cross-binding activity to VOCs than that of template antigen immunized serum; meanwhile, the candidate antigen immunized serum has the ability to block the combination of VOCs and ACE2. Therefore, the candidate antigen prepared by the application can become a potential universal antigen or combination for inducing cross-neutralization activity for preventing SARS-related coronavirus infection. The strategy of preparing the candidate antigen with cross-neutralization immunogenicity based on DNA Shuffling and membrane mutation antigen screening technology is expected to be applied to universal vaccine research and development. The candidate universal antigen prepared by the application has the potential to be developed into a SARS-related coronavirus universal vaccine.

The invention discloses a multi-epitope fusion protein for preventing infection of A-type to G-type clostridium perfringens and application, the multi-epitope fusion protein MVCP prepared by the invention is used for preventing infection of A-type to G-type clostridium perfringens of livestock and poultry, and the amino acid sequence of the fusion protein is as shown in SEQ ID NO: 1. Mouse experiments verify that hyper-immune serum prepared by using the fusion protein as an antigen can prevent infection of any one of A-type and G-type clostridium perfringens, meanwhile, after MVCP immunizes a female mouse, the female mouse can generate high-level IgG antibodies, the antibodies are effectively transmitted to a newborn mouse through milk, the newborn mouse obtains resistance to infection of the A-type clostridium perfringens, and the newborn mouse can be prevented from suffering from infection of the A-type clostridium perfringens. Therefore, the effectiveness of the protein in preventing young animals from being infected with clostridium perfringens is verified.